The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial

Abstract This open-label phase II trial (NCT04542837) aimed to evaluate the efficacy and safety of KN046 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC), and explore the potential response biomarkers. Participants received KN046 5 mg/kg every 3 weeks and lenvatinib...

Full description

Saved in:

Bibliographic Details
Main Authors:	Da Xu, Hongwei Wang, Quan Bao, Kemin Jin, Ming Liu, Wei Liu, Xiaoluan Yan, Lijun Wang, Yanqiao Zhang, Guangyu Wang, Yue Ma, Zhigang Ma, Chunhui Zhang, Jiebing Tang, Sha Wang, Jiaohui Pang, Ting Xu, Kun Wang, Baocai Xing
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-02-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-025-56537-y
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
by: Hiroyuki Iwasaki, et al.
Published: (2020-01-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01)

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Associations of CTLA4 Gene Polymorphisms with Graves’ Ophthalmopathy: A Meta-Analysis
by: Pengfei Du, et al.
Published: (2014-01-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

PRESENTATION OF THE BOOK «K.N. LEONTIEV. NOTES AND REPORTS»
by: N. V. Litvak
Published: (2013-12-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Optimization of fermentation conditions to increase the production of antifungal metabolites from Streptomyces sp. KN37
by: Xiaoyue Yang, et al.
Published: (2025-01-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Crystal structure of a polymorph of potassium picrate, C6H2KN3O7
by: Luo Xinyao, et al.
Published: (2023-08-01)

Approche lexico-cognitive des "mots en kn-’" du vocabulaire anglais
by: Line Argoud
Published: (2007-12-01)

Gastrointestinal symptoms and bowel habits in 53 046 healthy Danish blood donors: a nationwide cross-sectional study
by: Christian Erikstrup, et al.
Published: (2025-02-01)

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
by: Shixue Chen, et al.
Published: (2019-01-01)

On (k,kn-k2-2k-1)-Choosability of n-Vertex Graphs
by: Wongsakorn Charoenpanitseri
Published: (2015-01-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
by: Kuang Youlin, et al.
Published: (2012-01-01)

Conceptual Design of a 10 MW Multipurpose Research Reactor Using VVR-KN Fuel
by: Nhi-Dien Nguyen, et al.
Published: (2020-01-01)

Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy
by: Wenhua Xu, et al.
Published: (2020-01-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion
by: Chongwei Xie, et al.
Published: (2025-03-01)

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
by: Chiara Tuccilli, et al.
Published: (2018-01-01)

CTLA-4 Engagement Inhibits Th2 but not Th1 Cell Polarisation
by: Vanessa Ubaldi, et al.
Published: (2003-01-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy
by: Tian He, et al.
Published: (2025-01-01)

Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody
by: Liqiu Ma, et al.
Published: (2025-02-01)

Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01)

Two-Stage Humanitarian Logistics Deprivation Model for the Planning of Scarce KN-95 Facemask Supplies under Agent’s Cooperation
by: Oscar L. Pineda-Martinez, et al.
Published: (2021-01-01)

Increased Co-Expression of PD-L1 and CTLA-4 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
by: Chen C, et al.
Published: (2025-01-01)

Studi Eksperimen Pengaruh Penggunaan Koh Terhadap Performa Generator HHO Tipe Dry Cell Dengan Dimensi Setiap Plat 3.046,59 Mm2
by: R Nofriyandi
Published: (2017-08-01)

New bispecific antibodies in diffuse large B-cell lymphoma
by: Adrian G. Minson, et al.
Published: (2025-02-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01)

A Case of Multiple Intratumoral Hemorrhage and Rupture of Hepatocellular Carcinoma after Starting Lenvatinib
by: Katsutoshi Ishihara
Published: (2020-01-01)

Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer
by: Hajime Nakamura, et al.
Published: (2020-01-01)